Key facts
- It has raised $7.0M; the latest was Later Stage VC in Oct 2024.
- Notable investors include Scottish Enterprise, British Business Bank, Archangel Fund, Alderley Park, Archangel Investors — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for BDD
- ·The full record, as it builds
Funding rounds
No funding rounds for BDD are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BDD
Operator of a drug delivery platform intended to accelerate product development pipelines. The company's platform accelerates the evaluation and optimization of product performance using in vivo clinical data to direct formulation design in real time, enabling clients to significantly reduce the time from product concept to clinical success.
- Sector
- Healthcare
- HQ
- Glasgow, United Kingdom
- Founded
- 1999
- Employees
- 54
- Website
- bddpharma.com/
- Ownership
- Privately Held (backing)
BDD doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BDD shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BDD in its N-PORT filings yet. We sweep new filings monthly.